vTv Therapeutics to Participate in the 38th Annual ROTH Conference

vTv Therapeutics (Nasdaq: VTVT) said its management team will participate in a fireside chat and hold 1x1 investor meetings at the 38th Annual ROTH Conference in Dana Point, CA, March 22-24, 2026.

Rhea-AI Summary

vTv Therapeutics (Nasdaq: VTVT) said its management team will participate in a fireside chat and hold 1x1 investor meetings at the 38th Annual ROTH Conference in Dana Point, CA, March 22-24, 2026.

The fireside chat is scheduled for March 23, 2026 at 10:00 AM PDT and will be webcast live with a replay available on the company website.

Argus Mar 16 session

+14.57% close to close Open Argus

Details

News Market Reaction – VTVT

On Mar 16, the day this news came out, VTVT closed 14.57% above the previous close.

Data tracked by StockTitan Argus for the Mar 16 session.

Market Context

On Mar 16, the day this news came out, the stock closed 14.6% above the previous close. A strong pos...

Analysis

On Mar 16, the day this news came out, the stock closed 14.6% above the previous close. A strong positive reaction aligns with vTv’s history of favorable responses to partnership, clinical, and financing milestones, even though this announcement only highlights ROTH conference participation. Investors have previously rewarded progress around cadisegliatin and HPP737, but the existing S-3 registration for 15,876,640 shares and warrants underscores ongoing dilution capacity that could temper longer-term gains if utilized.

Key Figures

Conference edition: 38th Annual ROTH Conference Conference dates: March 22–24, 2026 Fireside chat date: Monday, March 23, 2026 +1 more

Conference edition

38th Annual ROTH Conference

Event where vTv will participate

Conference dates

March 22–24, 2026

Overall ROTH conference schedule in Dana Point, CA

Fireside chat date

Monday, March 23, 2026

Scheduled vTv fireside chat

Fireside chat time

10:00 AM PDT

Scheduled time for vTv’s session

Historical Context

5 past events · Latest: Mar 10

5 events

1. Mar 10

   Earnings and update

   24h Move

   +0.2%

   Q4 and 2025 results with cash position and CATT1 enrollment timing.

2. Feb 13

   Investor conferences

   24h Move

   -7.2%

   Planned participation in two investor conferences with webcast availability.

3. Feb 02

   License amendment

   24h Move

   +8.2%

   Expanded global license for HPP737 with upfront, milestone, and royalty economics.

4. Dec 18

   Phase 2 protocol

   24h Move

   +3.7%

   Submission of 12‑month, 300‑patient Phase 2 study protocol for cadisegliatin in T2D.

5. Nov 06

   Earnings and financing

   24h Move

   +2.2%

   Q3 results, $80M private placement, CATT1 progress, and long-dated patent allowance.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

type 1 diabetes

1 terms

type 1 diabetes medical

"therapy to insulin being investigated for the treatment of type 1 diabetes (T1D)"

An autoimmune condition in which the pancreas stops producing insulin, a hormone that lets the body use sugar for energy; without insulin people must manage blood sugar with injections, pumps, or other therapies. For investors, it matters because the lifelong need for medicines, devices, and monitoring creates steady demand, influences healthcare spending and reimbursement decisions, and drives clinical trials and regulatory activity in the diabetes treatment market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HIGH POINT, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in a fireside chat and conduct 1x1 investor meetings at the 38^th Annual ROTH Conference, which is being held March 22-24, 2026, in Dana Point, CA.

38th Annual ROTH Conference:
Format:	Fireside chat and 1x1 investor meetings
Date:	Monday, March 23, 2026
Time:	10:00 AM PDT
Webcast Link

A live webcast of the fireside chat will be available on the Media & Events section of the Company’s website at vtvtherapeutics.com. A replay of the webcast will be available following the event.

About vTv Therapeutics

vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a US Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.

About Cadisegliatin

Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the US as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin, acting selectively on the liver, increased the activity of glucokinase independently from insulin which supports clinical investigation of improvement in glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).

Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.

Investor Contact
John Fraunces
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com

Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will vTv Therapeutics (VTVT) present at the 38th Annual ROTH Conference?

vTv Therapeutics will present on March 23, 2026 at 10:00 AM PDT. According to the company, management will appear in a fireside chat and conduct 1x1 investor meetings during the March 22-24, 2026 conference in Dana Point, CA.

How can investors watch the vTv Therapeutics (VTVT) fireside chat webcast?

Investors can watch the fireside chat via a live webcast on the company website. According to the company, the webcast will be available on the Media & Events section of vtvtherapeutics.com, with a replay posted after the event.

What topics will vTv Therapeutics (VTVT) management likely discuss at the ROTH Conference?

Management will discuss company strategy and the development of cadisegliatin as an adjunctive therapy to insulin. According to the company, the fireside chat and 1x1 meetings focus on late-stage development of cadisegliatin for type 1 diabetes and investor engagement.

Will there be investor meetings for vTv Therapeutics (VTVT) at the ROTH Conference?

Yes, vTv Therapeutics management will hold one-on-one investor meetings during the conference. According to the company, management will conduct 1x1 investor meetings in addition to the March 23 fireside chat to engage with analysts and investors.

Where and when is the 38th Annual ROTH Conference taking place for VTVT attendees?

The conference runs March 22-24, 2026 in Dana Point, California. According to the company, vTv Therapeutics will participate on March 23, 2026, with the fireside chat slated for 10:00 AM PDT and additional investor meetings during the event.

Will a replay of the vTv Therapeutics (VTVT) ROTH fireside chat be available after the event?

Yes, a replay will be available following the live event on the company website. According to the company, the replay will be posted in the Media & Events section of vtvtherapeutics.com after the March 23 fireside chat concludes.